Rivaroxaban was the first orally dosed, direct Factor Xa inhibitor, a small-molecule oxazolidinone derivative. It binds directly and reversibly to Factor Xa via the S1 and S4 pockets.

Metabolism of this drug occurs in the liver via oxidative degradation catalyzed by CYP3A4/5 and CYP2J2 mechanism.

Excretion occurs mainly via urine 66% and party via feces 28%.